25.04

3.51% +0.85

After Hours: 25.16 0.12 +0.48%

ARK Genomic Revolution ETF (ARKG)

Overview News Price History Option Chain Discussions Forecast Dividend History

ARK Genomic Revolution ETF stock is currently priced at $25.04, with a 24-hour trading volume of 4.47M. It has seen a +3.51% increased in the last 24 hours and a -7.60% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $24.08 pivot point. If it approaches the $25.03 resistance level, significant changes may occur.

Previous Close:

$24.19

Open:

$25.02

24h Volume:

4.47M

Market Cap:

$N/A

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+8.02%

1M Performance:

-7.60%

6M Performance:

-3.84%

1Y Performance:

-13.24%

1D Range:

$24.88

$26.05

52W Range:

$21.97

$38.97

ARK Genomic Revolution ETF Stock (ARKG) Company Profile

Name

ARK Genomic Revolution ETF

Sector

Financial (4599)

Industry

Exchange Traded Fund (3101)

Phone

855-406-1506

Address

Employee

Twitter

@arkinvest

Next Earnings Date

Latest SEC Filings

ARKG's Discussions on Twitter

ARK Genomic Revolution ETF Stock (ARKG) Latest News

Cathie Wood's Ark Empire Bleeds As Investor Outflows Spike: 'The Loyal Shareholders Have Become Frustrated'

Benzinga

Cathie Wood's Ark Buys Roku, Palantir And $1M Worth Of Stock In This Healthcare Company

Benzinga

Cathie Wood's Ark Sheds Nearly $4M Nvidia Shares And Trims Position In This AI Peer

Benzinga

ARK Genomic Revolution ETF Stock (ARKG) Financials Data

There is no financial data for ARK Genomic Revolution ETF (ARKG). Check out other stocks for more information.

The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.